Skip to content
777 Sourcing.

Capability

antibody-based drug development

Suppliers
1
States & provinces
1
Countries
1

1 antibody-based drug development supplier across 1 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

CANTARGIA AB

LUND, LUND

Cantargia AB is a Swedish listed biotechnology company that develops antibody-based therapies targeting the IL1RAP molecule for the treatment of cancer as well as inflammatory and autoimmune diseases. The company has brought two candidate drugs into clinical development, nadunolimab (CAN04) and CAN10, and develops a preclinical project CAN14 derived from its CANxx antibody platform. Cantargia was founded in 2010 by researchers Thoas Fioretos, Marcus Järås and Kjell Sjöström based on research from Lund University, and is listed on Nasdaq Stockholm's Main

biomarker developmentclinical developmentcombination therapiesimmunotherapypreclinical research

Compiled from public sources

Related capabilities

Other processes offered by the shops that list antibody-based drug development.

Browse all capabilities